šŸ“Š This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Dice Therapeutics

1.1 - Company Overview

Dice Therapeutics Logo

Dice Therapeutics

Headquarter: United States
Founded: 20XXšŸ”’
Employees: 100-500šŸ”’
šŸŒ Website

Company description

  • Provider of oral small-molecule therapeutics for chronic autoimmune, inflammatory, and other diseases, leveraging a proprietary platform to build a pipeline targeting well-validated immunology pathways. Programs include IL-17 inhibitors (DC-806, DC-853) and novel scaffolds, oral Ī±4Ī²7 for IBD, oral Ī±VĪ²1/Ī±VĪ²6 for fibrotic diseases including idiopathic pulmonary fibrosis, and oral PD-L1 inhibitors for cancers.

Products and services

  • DC-806: Engineered as an oral small molecule IL-17 inhibitor, it treats psoriasis and other autoimmune diseases by blocking the IL-17 pathway
  • Oral Ī±4Ī²7 program: Developed as oral small molecule inhibitors targeting Ī±4Ī²7, these candidates address inflammatory bowel disease by antagonizing the Ī±4Ī²7 pathway
  • DC-853: Built as a small molecule IL-17 inhibitor with potentially improved metabolic-stability, it aims to treat autoimmune diseases by inhibiting the IL-17 target

Key contacts

šŸ”’
šŸ”’

Financial details

šŸ”’

1.2 - Competitors and similar companies to Dice Therapeutics

Xcovery Logo

Xcovery

HQ: United States Website
  • Description: Provider of low-toxicity, molecular-targeted oral cancer therapeutics, including Ensartinib for ALK-positive non-small cell lung cancer and Vorolanib, a VEGFR/PDGFR tyrosine kinase inhibitor for solid tumors such as renal cell carcinoma. Conducts clinical trials, seeks partnerships to launch Ensartinib globally and advance Vorolanib in combination therapy, and offers patient information and support resources.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Xcovery company profile ā†’
Circle Pharma Logo

Circle Pharma

HQ: United States Website
  • Description: Provider of bioavailable macrocyclic peptide therapeutics targeting intracellular protein-protein interactions, supported by the MXMO platform that combines computational structure-based design and synthetic chemistry to create cell-permeable macrocycles. Offers cyclin A/B inhibitors for cancers with Retinoblastoma pathway mutations and other tumors, advancing precision oncology and therapeutics for 'undruggable' targets.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Circle Pharma company profile ā†’
Antigen Express Logo

Antigen Express

HQ: United States Website
  • Description: Provider of proprietary vaccine formulation platform and products addressing large unmet medical needs by focusing on stimulation of critical T helper cells. The technology enables antigen-specific stimulation or suppression of T-helper responses to virtually any antigen.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Antigen Express company profile ā†’
Pionyr Logo

Pionyr

HQ: United States Website
  • Description: Provider of immuno-oncology therapeutics that enhance antitumor immunity by targeting the tumor microenvironment. Utilizes novel target discovery and antibody generation platforms and its Myeloid Tuning approach. Programs include PY314 (TREM2) to deplete tumor-associated macrophages, PY159 (TREM1) to repolarize them to counteract immunosuppression, and PY265 (MARCO) to activate immune responses.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Pionyr company profile ā†’
Gradalis Logo

Gradalis

HQ: United States Website
  • Description: Provider of personalized cancer immunotherapy leveraging patients' own genetically modified tumor cells to enhance immune recognition and killing through its Vigil platform, and of clinical trials evaluating the safety and efficacy of Vigil across cancer types, including ovarian cancer and Ewingā€™s sarcoma.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Gradalis company profile ā†’
šŸ”’

2.M&A buyers

2.1 Potential strategic acquirers in the sector

šŸ”’
šŸ”’
šŸ”’
šŸ”’ View all strategic buyers with complete profiles
Start Free Trial ā†’

2.2 - Strategic buyer groups for Dice Therapeutics

šŸ”’

Buyer group 1: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”’

Buyer group 2: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”’

Buyer group 3: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”“ Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial ā†’

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Dice Therapeutics

2.2 - Growth funds investing in similar companies to Dice Therapeutics

šŸ”’ View all growth equity funds with complete profiles
Start Free Trial ā†’

4 - Top valuation comps for Dice Therapeutics

4.2 - Public trading comparable groups for Dice Therapeutics

šŸ”“ Unlock all public trading comparable groups with complete valuation data
Start Free Trial ā†’

4.3 - M&A Transactions similar to Dice Therapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
šŸ”’ View all M&A transactions with complete deal terms
Request Free Trial Now ā†’

Frequently Asked Questions

About Dice Therapeutics

What does Dice Therapeutics do?

Dice Therapeutics is a provider of oral small-molecule therapeutics for chronic autoimmune, inflammatory, and other diseases, leveraging a proprietary platform to build a pipeline targeting well-validated immunology pathways. Programs include IL-17 inhibitors (DC-806, DC-853) and novel scaffolds, oral Ī±4Ī²7 for IBD, oral Ī±VĪ²1/Ī±VĪ²6 for fibrotic diseases including idiopathic pulmonary fibrosis, and oral PD-L1 inhibitors for cancers.

Who are Dice Therapeutics's competitors?

Dice Therapeutics's competitors and similar companies include Xcovery, Circle Pharma, Antigen Express, Pionyr, and Gradalis.

Where is Dice Therapeutics headquartered?

Dice Therapeutics is headquartered in United States.

How many employees does Dice Therapeutics have?

Dice Therapeutics has 1,000 employees šŸ”’.

When was Dice Therapeutics founded?

Dice Therapeutics was founded in 2010 šŸ”’.

What sector and industry vertical is Dice Therapeutics in?

Dice Therapeutics is in the Enterprise Software šŸ”’ sector and industry

M&A Buyers & Acquirers for Dice Therapeutics

Who are the top strategic acquirers in Dice Therapeutics's sector and industry

Top strategic M&A buyers and acquirers in Dice Therapeutics's sector include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Which M&A buyer groups are most relevant for Dice Therapeutics?

Top strategic M&A buyers groups and sectors for Dice Therapeutics include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ , ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Financial Investors investing in Dice Therapeutics's sector and industry vertical

Which are the top PE firms investing in Dice Therapeutics's sector and industry vertical?

Top PE firms investing in Dice Therapeutics's sector and industry vertical include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Who are the top buyout funds acquiring in Dice Therapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Dice Therapeutics's sector and industry vertical include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Who are the top growth equity funds investing in companies in Dice Therapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Dice Therapeutics include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Valuation benchmarks of companies in Dice Therapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Dice Therapeutics?

The key public trading comparables and valuation benchmarks for Dice Therapeutics include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Which are the key trading comparable groups for Dice Therapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Dice Therapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Dice Therapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Dice Therapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Dice Therapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Dice Therapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Dice Therapeutics